SNYNF
Sanofi
OTC Markets OTCPKUSDEQUITY
Healthcare
DELAYED
Strong sell
-68/100
Last price
77.48
▼ 1.01 (1.29%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Overlay another symbol
Both series are rebased to 0% at the left edge, so the lines show relative performance rather than price.
Tool
1D
—
H —
L —
Range —
Vol —
vs
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
—
Prev close
78.49
Day high
83.68
Day low
83.68
Volume
1
Market cap
$92.83B
P/E (TTM)
20.44
52W range
77.08 – 106.34
Trailing performance
Returnvs SPY
1W
-3.36%
-5.1%
1M
-13.21%
-14.5%
3M
-6.84%
-10.1%
6M
-18.67%
-33.4%
YTD
-20.37%
-34.1%
1Y
-23.91%
-39.4%
3Y
-26.54%
-108.1%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on SNYNF open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
123.56M
Total on file
Fundamentals
Market cap$92.83B
Enterprise value$110.41B
Revenue (TTM)$48.92B
Gross profit$35.93B
EBITDA$13.54B
Net income$3.94B
EPS (TTM)$3.79
Free cash flow$6.30B
Total cash$6.35B
Total debt$23.58B
Book value / share$67.20
Shares outstanding1.20B
Float1.08B
Short % of float—
Dividend yield6.25%
Beta (5Y)0.28
Valuation & profitability ratios
Trailing P/E20.44
Forward P/E8.38
PEG ratio26.61
Price / sales—
Price / book1.15
EV / revenue2.26
EV / EBITDA8.15
Gross margin73.45%
Operating margin21.03%
Profit margin8.09%
Return on equity5.71%
Return on assets5.09%
Debt / equity33.89
Current ratio0.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $46.72B | $44.29B | $41.62B | $40.56B | +5.5% |
| Operating revenue | $43.63B | $41.08B | $37.82B | $37.65B | +6.2% |
| Cost of revenue | $13.05B | $13.21B | $12.63B | $11.88B | -1.2% |
| Gross profit | $33.67B | $31.08B | $28.99B | $28.68B | +8.3% |
| Research & development | $7.84B | $7.39B | $6.51B | $6.50B | +6.1% |
| Selling, general & admin | $10.24B | $9.82B | $9.48B | $8.74B | +4.3% |
| Total operating expense | $24.07B | $22.16B | $20.30B | $17.75B | +8.6% |
| Operating income | $9.60B | $8.92B | $8.69B | $10.93B | +7.6% |
| Net interest income | -$129.00M | -$490.00M | -$626.00M | -$223.00M | +73.7% |
| Pre-tax income | $6.17B | $6.70B | $6.25B | $9.94B | -7.8% |
| Tax provision | $1.04B | $1.20B | $1.02B | $1.91B | -13.4% |
| Net income | $7.81B | $5.56B | $5.40B | $8.37B | +40.5% |
| Net income to common | $7.81B | $5.56B | $5.40B | $8.37B | +40.5% |
| Basic EPS | 6.40 | 4.59 | 4.31 | 5.37 | +39.4% |
| Diluted EPS | 6.37 | 4.59 | 4.31 | 5.37 | +38.8% |
| EBIT | $6.80B | $7.40B | $6.89B | $10.40B | -8.1% |
| EBITDA | $12.48B | $10.99B | $11.32B | $13.51B | +13.6% |
| Basic shares | 1.22B | 1.25B | 1.25B | 1.25B | -2.5% |
| Diluted shares | 1.23B | 1.25B | 1.25B | 1.25B | -2.1% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Cash & equivalents | $7.66B | $7.44B | $8.71B | $12.74B | +2.9% |
| Cash & short-term investments | $8.47B | $7.93B | $8.98B | $13.40B | +6.8% |
| Accounts receivable | $8.41B | $7.68B | $8.43B | $8.42B | +9.5% |
| Inventory | $10.21B | $9.43B | $9.67B | $8.96B | +8.3% |
| Total current assets | $30.95B | $42.59B | $30.67B | $34.11B | -27.3% |
| Property, plant & equipment | $11.51B | $11.60B | $11.81B | $11.68B | -0.8% |
| Goodwill & intangibles | $67.56B | $66.01B | $73.72B | $71.53B | +2.3% |
| Total assets | $126.81B | $132.80B | $126.46B | $126.72B | -4.5% |
| Total current liabilities | $28.34B | $29.16B | $24.21B | $23.97B | -2.8% |
| Current debt | $4.34B | $4.21B | $2.04B | $4.17B | +3.2% |
| Long-term debt | $14.25B | $11.79B | $14.35B | $14.86B | +20.8% |
| Total debt | $20.33B | $17.91B | $18.42B | $21.21B | +13.5% |
| Total liabilities | $55.09B | $54.94B | $52.11B | $51.57B | +0.3% |
| Shareholder equity | $71.38B | $77.51B | $74.04B | $74.78B | -7.9% |
| Working capital | $2.61B | $13.43B | $6.46B | $10.14B | -80.6% |
| Net tangible assets | $3.81B | $11.49B | $317.00M | $3.25B | -66.8% |
| Shares issued | 1.22B | 1.26B | 1.26B | 1.27B | -3.5% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | $4.94B | $5.50B | $5.06B | $7.97B | -10.1% |
| Depreciation & amortisation | $5.68B | $3.59B | $4.43B | $3.11B | +58.3% |
| Change in working capital | $1.79B | -$615.00M | $413.00M | -$794.00M | +391.9% |
| Operating cash flow | $10.75B | $9.08B | $10.26B | $10.53B | +18.4% |
| Capital expenditure | -$3.54B | -$3.19B | -$2.91B | -$2.10B | -10.7% |
| Investing cash flow | -$2.45B | -$4.41B | -$6.20B | -$2.08B | +44.5% |
| Share buybacks | -$5.03B | -$302.00M | -$593.00M | -$497.00M | -1,565.6% |
| Dividends paid | -$4.77B | -$4.70B | -$4.45B | -$4.17B | -1.4% |
| Financing cash flow | -$8.21B | -$5.76B | -$8.05B | -$5.82B | -42.4% |
| Free cash flow | $7.21B | $5.89B | $7.35B | $8.42B | +22.5% |
| End cash position | $7.66B | $7.44B | $8.71B | $12.74B | +2.9% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $12.30B | $11.24B | $12.21B | $13.17B | $10.73B | — | +9.4% |
| Operating revenue | $11.60B | $10.51B | $11.30B | $12.43B | $9.99B | — | +10.4% |
| Cost of revenue | $3.02B | $3.14B | $3.76B | $3.41B | $2.99B | — | -3.9% |
| Gross profit | $9.28B | $8.11B | $8.45B | $9.76B | $7.74B | — | +14.5% |
| Research & development | $2.23B | $1.75B | $2.29B | $1.83B | $1.91B | — | +27.8% |
| Selling, general & admin | $2.63B | $2.49B | $3.44B | $2.29B | $2.46B | — | +5.6% |
| Total operating expense | $6.90B | $5.84B | $6.82B | $5.97B | $5.80B | — | +18.2% |
| Operating income | $2.38B | $2.27B | $1.63B | $3.79B | $1.94B | — | +5.1% |
| Net interest income | -$210.00M | -$118.00M | $161.00M | -$113.00M | -$50.00M | — | -78.0% |
| Pre-tax income | $837.00M | $2.00B | -$917.00M | $3.51B | $1.42B | — | -58.2% |
| Tax provision | $451.00M | $420.00M | -$348.00M | $680.00M | $230.00M | — | +7.4% |
| Net income | $343.00M | $1.61B | -$801.00M | $2.80B | $3.94B | — | -78.7% |
| Net income to common | $343.00M | $1.61B | -$801.00M | $2.80B | $3.94B | — | -78.7% |
| Basic EPS | 0.29 | 1.34 | -0.66 | — | 3.24 | 1.52 | -78.4% |
| Diluted EPS | 0.29 | 1.34 | -0.66 | — | 3.24 | 1.52 | -78.4% |
| EBIT | $1.12B | $2.18B | -$879.00M | $3.74B | $1.57B | — | -48.5% |
| EBITDA | $1.68B | $2.72B | -$341.00M | $4.20B | $1.95B | — | -38.3% |
| Basic shares | 1.20B | 1.20B | 1.21B | — | 1.22B | 1.23B | -0.6% |
| Diluted shares | 1.20B | 1.20B | 1.21B | — | 1.22B | 1.23B | -0.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $6.35B | $5.54B | $7.66B | $8.91B | $15.36B | +14.5% |
| Cash & short-term investments | $6.35B | $5.54B | $8.47B | $8.91B | $15.36B | +14.5% |
| Accounts receivable | $8.71B | — | $8.41B | — | $7.81B | — |
| Inventory | $24.12B | $23.50B | $10.21B | $24.50B | $9.62B | +2.6% |
| Total current assets | $31.52B | $30.16B | $30.95B | $34.04B | $37.02B | +4.5% |
| Property, plant & equipment | $11.95B | $11.67B | $11.51B | $11.18B | $11.01B | +2.4% |
| Goodwill & intangibles | $68.31B | $69.09B | $67.56B | $68.87B | $60.71B | -1.1% |
| Total assets | $129.06B | $128.02B | $126.81B | $129.79B | $124.96B | +0.8% |
| Total current liabilities | $31.93B | $30.01B | $28.34B | $32.10B | $29.06B | +6.4% |
| Current debt | $7.03B | $5.92B | $4.34B | $8.20B | $7.31B | +18.7% |
| Long-term debt | $14.65B | $12.30B | $14.25B | $11.70B | $13.20B | +19.1% |
| Total debt | $23.58B | $20.02B | $20.33B | $21.75B | $22.29B | +17.8% |
| Total liabilities | $59.49B | $54.88B | $55.09B | $56.26B | $54.68B | +8.4% |
| Shareholder equity | $69.21B | $72.81B | $71.38B | $73.26B | $70.01B | -4.9% |
| Working capital | -$408.00M | $156.00M | $2.61B | $1.94B | $7.96B | -361.5% |
| Net tangible assets | $894.00M | $3.72B | $3.81B | $4.40B | $9.29B | -76.0% |
| Shares issued | 1.23B | 1.21B | 1.22B | 1.23B | 1.23B | +1.6% |
| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | YoY |
|---|---|---|---|---|---|---|
| Operating cash flow | $2.96B | $1.68B | $3.44B | $3.75B | $1.46B | +75.9% |
| Investing cash flow | -$365.00M | -$2.28B | -$2.13B | -$9.04B | $9.50B | +84.0% |
| Financing cash flow | -$1.80B | -$1.53B | -$2.57B | -$1.15B | -$3.90B | -18.2% |
| Free cash flow | $1.66B | $1.68B | -$93.00M | $3.75B | $1.46B | -1.1% |
| End cash position | $6.35B | $5.54B | $7.66B | $8.91B | $15.36B | +14.5% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
—
—
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | — | — | $13.16B | +5.8% |
| Next quarter | — | — | $12.53B | +10.9% |
| Current year | — | — | $47.72B | +9.4% |
| Next year | — | — | $50.71B | +6.3% |
Analyst targets & ownership
Mean target—
High target—
Low target—
Implied upside—
Analyst count—
ConsensusNONE
Strong buy / Buy— / —
Hold—
Sell / Strong sell— / —
Held by insiders10.31%
Held by institutions42.30%
Institutions holding846
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
79.87
-3.00% from price
SMA 20
82.46
-6.04% from price
SMA 50
85.96
-9.87% from price
SMA 100
86.21
-10.12% from price
SMA 200
89.61
-13.54% from price
EMA 12
80.50
-3.75% from price
EMA 26
82.92
-6.56% from price
EMA 50
84.74
-8.57% from price
RSI (14)
32.1
Neutral
MACD (12,26,9)
-2.42
Hist -0.44
ATR (14)
1.79
2.31% of price
Realised vol 30D
26.9%
Annualised
Bollinger upper
88.21
20, 2σ
Bollinger lower
76.71
20, 2σ
50 / 200 cross
Death
85.96 vs 89.61
Trend bias
Below 200
-13.54%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
0.04
Less volatile than market
Correlation to SPY
0.02
Largely independent
Realised vol 30D
26.9%
Annualised
Market vol 1Y
13.0%
SPY, annualised
Max drawdown 1Y
-26.2%
Peak to trough
Max drawdown 5Y
-36.2%
Peak to trough
ATR 14
1.79
2.31% of price
Beta (reported)
0.28
5Y monthly, from filing
Dividends & splits
Forward rate$4.84 / yr
Forward yield6.25%
5-year avg yield4.02%
Payout ratio126.68%
Ex-dividend dateMay 5, 2026
Next pay dateMay 15, 2018
Last split1005:1000
Split dateMay 6, 2022
Headlines
Plozasiran Sales Forecast and Market Size Analysis - 2034 Report Reveals How Quarterly Dosing and Up to 74% Triglyceride Reduction Position Arrowhead's siRNA Across the 7MM
GlobeNewswire · 2h ago
Expanded Sanofi Alliance And New Pipeline Data Could Be A Game Changer For Regeneron (REGN)
Simply Wall St. · 15h ago
Health Care Roundup: Market Talk
The Wall Street Journal · 16h ago
Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
Zacks · 1d ago
Press Release : Availability of the aide-mémoire for Q3 2026 results
GlobeNewswire · 1d ago
Housekeeping Starts with Branding: Vicapsys Life Sciences Adopts New Corporate Identity Developed by FutureBrand for Vicapsys and Its Stateline Subsidiary
ACCESS Newswire · 2d ago
Stocktwits Biotech Dealmaker — Novartis, Sanofi And Novo Sign Week’s Biggest Deals
Stocktwits · 5d ago
An $8 Billion Reason Why Regeneron Stock Is in Focus
Barchart · 5d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.